Abstract:Objectives Anaplastic lymphoma kinase (ALK) rearrangement status examination has been widely used in clinic for non-small cell lung cancer (NSCLC) patients in order to find patients that can be treated with targeted ALK inhibitors. This study intended to non-invasively predict the ALK rearrangement status in lung adenocarcinomas by developing a machine learning model that combines PET/CT radiomic features and clinical characteristics. Methods Five hundred twenty-six patients of lung adenocarcinoma with PET/CT scan examination were enrolled, including 109 positive and 417 negative patients for ALK rearrangements from February 2016 to March 2019. The Artificial Intelligence Kit software was used to extract radiomic features of PET/CT images. The maximum relevance minimum redundancy (mRMR) and least absolute shrinkage and selection operator (LASSO) logistic regression were further employed to select the most distinguishable radiomic features to construct predictive models. The mRMR is a feature selection method, which selects the features with high correlation to the pathological results (maximum correlation), meanwhile retain the features with minimum correlation between them (minimum redundancy). LASSO is a statistical formula whose main purpose is the feature selection and regularization of data model. LASSO method regularizes model parameters by shrinking the regression coefficients, reducing some of them to zero. The feature selection phase occurs after the shrinkage, where every non-zero value is selected to be used in the model. Receiver operating characteristic (ROC) analysis was used to evaluate the performance of the models, and the performance of different models was compared by the DeLong test. Results A total of 22 radiomic features were extracted from PET/CT images for constructing the PET/CT radiomic model, and majority of these features used were based on CT features (20 out of 22), only 2 PET features were included (PET percentile 10 and PET difference entropy). Moreover, three clinical features associated with ALK mutation (age, burr and pleural effusion) were also employed to construct a combined model of PET/CT and clinical model. We found that this combined model PET/CT-clinical model has a significant advantage to predict the ALK mutation status in the training group (AUC = 0.87) and the testing group (AUC = 0.88) compared with the clinical model alone in the training group (AUC = 0.76) and the testing group (AUC = 0.74) respectively. However, there is no significant difference between the combined model and PET/CT radiomic model. Conclusions This study demonstrated that PET/CT radiomics-based machine learning model has potential to be used as a non-invasive diagnostic method to help diagnose ALK mutation status for lung adenocarcinoma patients in the clinic.

Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naïve advanced lung adenocarcinoma.

Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement

Association of EGFR Mutation or ALK Rearrangement with Expression of DNA Repair and Synthesis Genes in Never‐smoker Women with Pulmonary Adenocarcinoma

Comparison of ALK Status Between Primary and Corresponding Lymph Node Metastatic Tumors in Lung Cancer Patients

Prognostic Significance of Anaplastic Lymphoma Kinase Rearrangement in Patients with Completely Resected Lung Adenocarcinoma

Clinical Characteristics and Progression of Pre-/Minimally Invasive Lung Adenocarcinoma Harboring ALK or RET Rearrangements: a Retrospective Cohort Study.

Clinicopathologic Characteristics of ALK Rearrangements in Primary Lung Adenocarcinoma with Identified EGFR and KRAS Status.

Correlation of FDG PET/CT, tumor markers and Ki-67 index with EGFR mutation or positive ALK expression in patients with non-small cell lung cancer

Clinicopathological and Demographical Characteristics of Non-Small Cell Lung Cancer Patients with ALK Rearrangements: a Systematic Review and Meta-Analysis.

Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring Alk Rearrangements Detected by Fish, Ihc, and Rt-Pcr

Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma

Eml4-Alk Rearrangement And Its Clinical Significance In Chinese Patients With Advanced Non-Small Cell Lung Cancer

Clinical Characteristics Associated with Metastatic Nsclc Harboring Alk Rearrangements in Chinese Patients.

A Survival Comparison Study of Chinese Patients with Primary Lung Adenocarcinoma Harboring ALK Rearrangements with Crizotinib Treatment Detected by FISH, IHC, and RT-PCR.

Clinicopathological Features of ALK Expression in 9889 Cases of Non-small-Cell Lung Cancer and Genomic Rearrangements Identified by Capture-Based Next-Generation Sequencing: A Chinese Retrospective Analysis.

A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts ALK Rearrangement Status in Lung Adenocarcinoma

CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas

Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase ( <i> <scp>ALK</scp> </i> )‐rearranged non‐small cell lung cancer

[Anaplastic Lymphoma Kinase-Positive Adenocarcinoma of Lung: a Cytopathologic Analysis].

P1.03-04 Molecular Characteristics of ALK Primary Point Mutations Non-Small-Cell Lung Cancer in Chinese Patients